High Diagnostic Performance of Short Magnetic Resonance Imaging Protocols for Prostate Cancer Detection in Biopsy-naïve Men: The Next Step in Magnetic Resonance Imaging Accessibility.


Journal

European urology
ISSN: 1873-7560
Titre abrégé: Eur Urol
Pays: Switzerland
ID NLM: 7512719

Informations de publication

Date de publication:
11 2019
Historique:
received: 25 02 2019
accepted: 17 05 2019
pubmed: 7 6 2019
medline: 31 10 2020
entrez: 7 6 2019
Statut: ppublish

Résumé

To make magnetic resonance imaging (MRI) more accessible to men at risk of high-grade prostate cancer (PCa), there is a need for quicker, simpler, and less costly MRI protocols. To compare the diagnostic performance of monoplanar ("fast" biparametric MRI [bp-MRI]) and triplanar noncontrast bp-MRI with that of the current contrast-enhanced multiparametric MRI (mp-MRI) in the detection of high-grade PCa in biopsy-naïve men. A prospective, multireader, head-to-head study included 626 biopsy-naïve men, between February 2015 and February 2018. Men underwent prebiopsy contrast-enhanced mp-MRI. Prior to biopsy, two blinded expert readers subsequently assessed "fast" bp-MRI, bp-MRI, and mp-MRI. Thereafter, systematic transrectal ultrasound-guided biopsies (SBs) were performed. Men with suspicious mp-MRI (Prostate Imaging Reporting and Data System 3-5 lesions) also underwent MR-in-bore biopsy (MRGB). Primary outcome was the diagnostic performance of each protocol for the detection of high-grade PCa. Secondary outcomes included the difference in biopsy avoidance, detection of low-grade PCa, acquisition times, decision curve analyses, inter-reader agreement, and direct costs. Results from combined MRGB and SB were used as the reference standard. High-grade PCa was defined as grade ≥2. Sensitivity for high-grade PCa for all protocols was 95% (180/190; 95% confidence interval [CI]: 91-97%). Specificity was 65% (285/436; 95% CI: 61-70%) for "fast" bp-MRI and 69% (299/436; 95% CI: 64-73%) for bp-MRI and mp-MRI. With fast bp-MRI, 0.96% (6/626) more low-grade PCa was detected. Biopsy could be avoided in 47% for the fast bp-MRI and in 49% for the bp-MRI and mp-MRI protocols. Fast bp-MRI and bp-MRI can be performed in 8 and 13min, respectively, instead of 16min at lower direct costs. Inter-reader agreement was 90% for fast bp-MRI protocol and 93% for bp-MRI protocol. A main limitation is the generalizability of these results in less experienced centers. Short MRI protocols can improve prostate MRI accessibility at a lower direct cost. For fast bp-MRI, this is at the cost of ∼2% more biopsies and ∼1% more overdetection of low-grade PCa. In order to implement this technique in nonexpert, low-volume, lower-field-strength scanners, further prospective studies have to be performed. We compared the value of three different magnetic resonance imaging (MRI) protocols for the detection of prostate cancer in men with elevated prostate-specific antigen levels. Our results show that, when used in expert centers, shorter MRI protocols do not compromise the detection of harmful disease. This increases MRI capacity at lower direct costs.

Sections du résumé

BACKGROUND
To make magnetic resonance imaging (MRI) more accessible to men at risk of high-grade prostate cancer (PCa), there is a need for quicker, simpler, and less costly MRI protocols.
OBJECTIVE
To compare the diagnostic performance of monoplanar ("fast" biparametric MRI [bp-MRI]) and triplanar noncontrast bp-MRI with that of the current contrast-enhanced multiparametric MRI (mp-MRI) in the detection of high-grade PCa in biopsy-naïve men.
DESIGN, SETTING, AND PARTICIPANTS
A prospective, multireader, head-to-head study included 626 biopsy-naïve men, between February 2015 and February 2018.
INTERVENTION
Men underwent prebiopsy contrast-enhanced mp-MRI. Prior to biopsy, two blinded expert readers subsequently assessed "fast" bp-MRI, bp-MRI, and mp-MRI. Thereafter, systematic transrectal ultrasound-guided biopsies (SBs) were performed. Men with suspicious mp-MRI (Prostate Imaging Reporting and Data System 3-5 lesions) also underwent MR-in-bore biopsy (MRGB).
OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS
Primary outcome was the diagnostic performance of each protocol for the detection of high-grade PCa. Secondary outcomes included the difference in biopsy avoidance, detection of low-grade PCa, acquisition times, decision curve analyses, inter-reader agreement, and direct costs. Results from combined MRGB and SB were used as the reference standard. High-grade PCa was defined as grade ≥2.
RESULTS AND LIMITATIONS
Sensitivity for high-grade PCa for all protocols was 95% (180/190; 95% confidence interval [CI]: 91-97%). Specificity was 65% (285/436; 95% CI: 61-70%) for "fast" bp-MRI and 69% (299/436; 95% CI: 64-73%) for bp-MRI and mp-MRI. With fast bp-MRI, 0.96% (6/626) more low-grade PCa was detected. Biopsy could be avoided in 47% for the fast bp-MRI and in 49% for the bp-MRI and mp-MRI protocols. Fast bp-MRI and bp-MRI can be performed in 8 and 13min, respectively, instead of 16min at lower direct costs. Inter-reader agreement was 90% for fast bp-MRI protocol and 93% for bp-MRI protocol. A main limitation is the generalizability of these results in less experienced centers.
CONCLUSIONS
Short MRI protocols can improve prostate MRI accessibility at a lower direct cost. For fast bp-MRI, this is at the cost of ∼2% more biopsies and ∼1% more overdetection of low-grade PCa. In order to implement this technique in nonexpert, low-volume, lower-field-strength scanners, further prospective studies have to be performed.
PATIENT SUMMARY
We compared the value of three different magnetic resonance imaging (MRI) protocols for the detection of prostate cancer in men with elevated prostate-specific antigen levels. Our results show that, when used in expert centers, shorter MRI protocols do not compromise the detection of harmful disease. This increases MRI capacity at lower direct costs.

Identifiants

pubmed: 31167748
pii: S0302-2838(19)30436-1
doi: 10.1016/j.eururo.2019.05.029
pii:
doi:

Substances chimiques

Prostate-Specific Antigen EC 3.4.21.77

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

574-581

Commentaires et corrections

Type : CommentIn
Type : CommentIn
Type : CommentIn
Type : CommentIn
Type : CommentIn
Type : CommentIn

Informations de copyright

Copyright © 2019 The Authors. Published by Elsevier B.V. All rights reserved.

Auteurs

Marloes van der Leest (M)

Department of Radiology and Nuclear Medicine, Radboud University Medical Center, Nijmegen, The Netherlands. Electronic address: marloes.vanderleest@radboudumc.nl.

Bas Israël (B)

Department of Radiology and Nuclear Medicine, Radboud University Medical Center, Nijmegen, The Netherlands; Department of Urology, Radboud University Medical Center, Nijmegen, The Netherlands.

Erik Bastiaan Cornel (EB)

Department of Urology, Ziekenhuis Groep Twente, Almelo-Hengelo, The Netherlands.

Patrik Zámecnik (P)

Department of Radiology and Nuclear Medicine, Radboud University Medical Center, Nijmegen, The Netherlands.

Ivo G Schoots (IG)

Department of Radiology and Nuclear Medicine, Erasmus University Medical Center, Rotterdam, The Netherlands.

Hans van der Lelij (H)

Department of Radiology and Nuclear Medicine, Maasstad Hospital, Rotterdam, The Netherlands.

Anwar R Padhani (AR)

Paul Strickland Scanner Centre, Mount Vernon Cancer Centre, Northwood, UK.

Maroeska Rovers (M)

Department of Operating Rooms, Radboud University Medical Center, Nijmegen, The Netherlands.

Inge van Oort (I)

Department of Urology, Radboud University Medical Center, Nijmegen, The Netherlands.

Michiel Sedelaar (M)

Department of Urology, Radboud University Medical Center, Nijmegen, The Netherlands.

Christina Hulsbergen-van de Kaa (C)

Laboratory Pathology Oost-Nederland, Hengelo, The Netherlands.

Gerjon Hannink (G)

Department of Operating Rooms, Radboud University Medical Center, Nijmegen, The Netherlands.

Jeroen Veltman (J)

Department of Radiology, Ziekenhuis Groep Twente, Almelo-Hengelo, The Netherlands.

Jelle Barentsz (J)

Department of Radiology and Nuclear Medicine, Radboud University Medical Center, Nijmegen, The Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH